BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
January 25, 2024 01:00 ET
|
BioSenic
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee...
PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
January 23, 2024 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
Osteoporosis Drugs Market Size Worth USD 20.53 Billion in 2032 | Emergen Research
January 18, 2024 10:15 ET
|
Emergen Research
Vancouver, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The global osteoporosis drugs market size was USD 13.06 billion in 2022 and is expected to register a revenue CAGR of 4.7% during the forecast period....
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
January 17, 2024 08:00 ET
|
Enlivex Therapeutics Ltd
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel,...
PETVIVO HOLDINGS, INC. TO EXHIBIT AT VETERINARY MEETING AND EXPO CONFERENCE IN ORLANDO, FLORIDA
January 09, 2024 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Jan. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative...
PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH COVETRUS NORTH AMERICA, LLC
December 22, 2023 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Dec. 22, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative...
PetVivo Holdings, Inc. Achieves Distribution Milestone Surpassing 4500 Syringes of Spryng™ in 2023
December 21, 2023 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Dec. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of...
PetVivo Holdings, Inc. Achieves National Distribution of Spryng™ to More than 600 Veterinary Clinics in 49 States
December 11, 2023 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Dec. 11, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging biomedical device company focused on the commercialization of...
PetVivo Holdings, Inc. to Exhibit at American Association of Equine Practitioners Conference in San Diego, California
November 21, 2023 11:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Nov. 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
PetVivo Reports Second Quarter of Fiscal 2024 Financial Results
November 14, 2023 15:00 ET
|
PetVivo Holdings, Inc.
Conference call begins at 4:00 p.m. Central time today EDINA, MN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the...